Research on the epigenetic modification of pancreatic cancer vaccine.

Wei Cao, Guoxiong Zhou, J. Qiu, Liangfeng Xu, Xiaoling Ding, Haifeng Zhang, Xiaorong Zhou

Research output: Contribution to journalArticle

Abstract

Pancreatic cancer is characterized as a type of gastrointestinal tumor with a poor prognosis and high degree of malignancy. CIITA gene was found highly methylated in pancreatic carcinoma cell line PANC-1 and responsible for the low expression of MHC-II that may lead to immune evasion. Here, we tried to prepare pancreatic cancer vaccine with PANC-1 cells via epigenetic modification to enhance the MHC-II expression. Then the vaccine was injected into C57BL/6J mice and the effect was examined. Our study found that the vaccine could promote the proliferation of antigen-specific T cells, enhance the killing activity of cytotoxic lymphocytes (CTL), promote Th1-type cells mediated secretion of cytokines IFN-gamma and IL-2 while inhibiting Th2-type cells mediated secretion of IL-4, and inhibit the secretion of TGF-beta. Generally, the epigenetically modified vaccine could enhance the body's anti-tumor immune response, providing feasibility research on cancer vaccine for therapy of pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)272-277
Number of pages6
JournalHepato-gastroenterology
Volume61
Issue number130
StatePublished - Jan 1 2014

    Fingerprint

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Cao, W., Zhou, G., Qiu, J., Xu, L., Ding, X., Zhang, H., & Zhou, X. (2014). Research on the epigenetic modification of pancreatic cancer vaccine. Hepato-gastroenterology, 61(130), 272-277.